Shop for $75 or more and get 13% off
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      DRL's R&D spend at 15% of net sales in '05

      Posted AtThe Economic Times

      Drug companies are pouring funds into R&D both in India and abroad. Ranbaxy, Cipla, Dr Reddy's Laboratories, Nicholas Piramal and Sun Pharma's research and development expenses have increased from Rs 585 crore in FY04 to Rs 859 crore in FY05, a 47% increase in a single year.

      Growth in R&D is where major differences emerge. GlaxoSmithKline and Pfizer's R&D expenses have not increased much in FY04, though Merck's has increased significantly. In contrast, Indian companies' R&D expenses have increased anywhere between 40% and 90%.

      Then again, not all companies are spending a similar share of sales on research. While Dr Reddy's Laboratories' R&D expenses amounted to 14.7% of its net sales in FY05, Nicholas Piramal and Cipla still spend less than 5% of their net sales on research.

      Along with current R&D expenses, Indian companies have also been spending significant amounts on R&D capital expenditure.

      With the setting up of modern facilities, capital expenditure on R&D has steadily increased over the past two years, adding up to Rs 182 crore for the top five Indian pharma companies for FY05. Ranbaxy has notably spent up to Rs 130 crore on capital expenditure on R&D over the past three years.

      In terms of research areas, MNCs and domestic companies have differing focal points. MNCs mainly work on the central nervous system, internal medicine, vaccines, oncology and metabolic disorders. Sanofi-Aventis and GlaxoSmithKline are respectively developing 26 and 32 new drugs for the central nervous system, 25 and 24 for internal medicine, and 18 and 20 new vaccines.

      As for Indian companies, their research is largely centred around metabolic and cardiovascular, infectious, urology, oncology and finally respiratory diseases. New Drug Delivery System (NDDS), generic products and contract research areas like developing non-infringing processes in the area of Active Pharmaceutical Ingredients (APIs) manufacture for MNCs, are today key areas for the Indian pharmaceutical industry.


      September 21, 2005

       

      Share this Article!

    Back to top^